1-苯基-1-环己基甲腈 | 2201-23-2

• 物质功能分类: 化学试剂 - 有机试剂 - 氰化物/腈
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯基-1-环己基甲腈
• 中文别名: 1-苯基环己腈；1-苯基-1-环己烷甲腈
• 英文名称: 1-phenyl-1-cyclohexanecarbonitrile
• 英文别名: 1-Phenylcyclohexanecarbonitrile；1-phenylcyclohexane-1-carbonitrile；1-Phenyl-cyclohexancarbonitril；1-Phenyl-cyclohexan-1-carbonitril
• CAS: 2201-23-2
• 化学式: C₁₃H₁₅N
• 分子量: 185.269
• InChiKey: AUXIEQKHXAYAHG-UHFFFAOYSA-N

物化性质

• 沸点：
  141°C/7mmHg(lit.)
• 密度：
  1.01
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2926909090
• 储存条件：
  密封存储，应存放在阴凉干燥的库房中。

SDS

Name:	1-Phenyl-1-cyclohexanecarbonitrile 97% Material Safety Data Sheet
Synonym:	None
CAS:	2201-23-2

Section 1 - Chemical Product MSDS Name:1-Phenyl-1-cyclohexanecarbonitrile 97% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2201-23-2	1-Phenyl-1-cyclohexanecarbonitrile	97.0	218-608-1

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2201-23-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.0170g/cm3
Molecular Formula: C13H15N
Molecular Weight: 185.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2201-23-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Phenyl-1-cyclohexanecarbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2201-23-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2201-23-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2201-23-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯基-1-环己基甲腈 在 二异丁基氢化铝 作用下， 生成 1-苯基环己烷-1-甲醛
  参考文献：
  名称：

  Fe催化的α-芳基醛的区域发散[1,2]-位移

  摘要：

  已经开发了通过 [1,2] 转移将醛催化转化为酮的方法。这种骨架重排显示出广泛的底物范围和化学选择性特征，同时表现出优异的 [1,2]-芳基或 [1,2]-烷基转移选择性，可通过电子效应轻松切换。

  DOI：

  10.1021/ja4068707
• 作为产物：
  描述：

  1-氰基环己烷羧酸乙酯 在 bis(η3-allyl-μ-chloropalladium(II)) 、 potassium tert-butylate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 乙醇 、 水 、 均三甲苯 为溶剂， 反应 10.17h， 生成 1-苯基-1-环己基甲腈
  参考文献：
  名称：

  钯乙酸盐与芳基卤化物和三氟甲磺酸酯的钯催化脱羧偶联合成α-芳基腈

  摘要：

  值得其盐：描述了氰基乙酸盐及其与芳基氯化物，溴化物和三氟甲磺酸酯的钯催化的脱羧偶联反应（参见方案）。该反应对于制备各种α-芳基腈具有潜在的实用性，并具有良好的官能团耐受性。S-Phos = 2-（（2,6-二甲氧基联苯）二环己基膦），Xant-Phos = 4,5-双（二苯基膦基）-9,9-二甲基x吨。

  DOI：

  10.1002/anie.201006763

文献信息

• Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents
  作者：Bharat K. Trivedi、Ann Holmes、Terri L. Stoeber、C. John Blankley、W. Howard Roark、Joseph A. Picard、Mary K. Shaw、Arnold D. Essenburg、Richard L. Stanfield、Brian R. Krause

  DOI：10.1021/jm00074a011

  日期：1993.10

  We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity

  我们合成了一系列的N-苯基-N'-芳烷基和N-苯基-N'-（1-苯基环烷基）脲作为酰基辅酶A：胆固醇酰基转移酶（ACAT）的抑制剂。人们认为这种细胞内酶负责饮食中胆固醇的酯化。因此抑制这种酶可以减少饮食引起的高胆固醇血症。对于这一系列化合物，通过增加苯环上2,6-取代基的体积来提高体外ACAT抑制活性。此外，我们发现芳环的间距对于ACAT抑制活性至关重要。离必需的2,6-二异丙基苯基部分5个原子的苯环对于体外活性而言是最佳的。N'-苯基部分被α取代增强了体外效能。就苯基环烷基脲而言，ACAT抑制活性与环烷基环的大小无关。从该系列类似物中，发现在高胆固醇血症动物模型中以50 mg / kg的饮食施用时，具有出色的体外抑制ACAT效力的化合物25在体内可使血浆胆固醇降低73％。在此模型中，化合物25依赖于降低血浆胆固醇剂量，并且与Lederle ACAT抑制剂CL 277082一样有效。
• Efficient and scalable synthesis of ketones via nucleophilic Grignard addition to nitriles using continuous flow chemistry
  作者：Carlos Mateos、Juan A. Rincón、José Villanueva

  DOI：10.1016/j.tetlet.2013.02.069

  日期：2013.5

  In the present Letter we report the development of efficient continuous flow chemistry conditions for the scalable preparation of ketones. This transformation is achieved via nucleophilic addition of Grignard reagents to the corresponding nitriles and imine hydrolysis by means of in-series plug flow reactors.

  在本函中，我们报告了可扩展制备酮的有效连续流化学条件的发展。这种转化是通过将Grignard试剂亲核加成到相应的腈中并通过串联活塞流反应器进行亚胺水解来实现的。
• Synthetic studies of marine alkaloids hapalindoles. Part I Total synthesis of (±)-hapalindoles J and M
  作者：Hideaki Muratake、Mitsutaka Natsume

  DOI：10.1016/s0040-4020(01)96005-3

  日期：——

  The first concise synthesis of marine indole alkaloids (±)-hapalindoles J (4) and M (5) was achieved in seven or six steps starting from a readily available compound 6 using important key reactions, 6 → 7 → and 8 and 35 → 41 or 5.

  海洋吲哚生物碱（±）-单吲哚J（4）和M（5）的第一个简明合成是通过使用重要的关键反应6→7→以及8和35→从现成的化合物6开始以七六步完成的41或5。
• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• Fluoro-substituted alkenyl compounds, liquid crystal compositions, and liquid crystal display elements
  申请人：——

  公开号：US20020015805A1

  公开（公告）日：2002-02-07

  The invention relates to a fluoro-substituted alkenyl compound represented by formula (1) 1 wherein Y 1 , Y 2 , Y 3 and Y 4 are each independently H or F, provided that at least one of Y 1 and Y 2 is F; Q 1 is a single bond or an alkylene group of 1-20 carbon atoms, at least one —CH 2 — being optionally substituted by —O—, provided that two or more —O— are not adjacent to each other; Q 2 is a single bond or —C≡C—; Rings A 1 , A 2 and A 3 are each independently a cyclohexane ring, a dioxane ring, a cyclohexene ring, a pyrimidine ring, a pyridine ring, or a benzene ring, or a benzene ring having at least one hydrogen atom substituted by F; Z 1 , Z 2 and Z 3 are each independently a single bond, —CH 2 CH 2 —, —CH 2 O—, —OCH 2 —, —COO—, —OCO—, —CH═CH—, —C≡C—, —CF 2 O—, or —OCF 2 ; and m and n are each independently 0 or 1; provided that Y 3 is F when Ring A 3 is a cyclohexane ring and Z 3 is a single bond. The liquid crystal composition comprising the compound, when used in liquid crystal display elements for various modes, excels in driving voltage and contrast.

  该发明涉及一种由式（1）表示的含氟取代烯基化合物 1 其中Y 1 ，Y 2 ，Y 3 和Y 4 分别独立地为H或F，但至少其中之一为F；Q 1 为1-20个碳原子的单键或烷基基团，至少一个—CH 2 —可选择地被—O—取代，但两个或更多个—O—不相邻；Q 2 为单键或—C≡C—；环A 1 ，A 2 和A 3 分别独立地为环己烷环，二氧六环，环己烯环，嘧啶环，吡啶环或苯环，或至少有一个氢原子被F取代的苯环；Z 1 ，Z 2 和Z 3 分别独立地为单键，—CH 2 CH 2 —，—CH 2 O—，—OCH 2 —，—COO—，—OCO—，—CH═CH—，—C≡C—，—CF 2 O—或—OCF 2 ；m和n分别独立地为0或1；但当环A 3 为环己烷环且Z 3 为单键时，Y 3 为F。包括该化合物的液晶组合物，在用于各种模式的液晶显示元件时，具有出色的驱动电压和对比度。

表征谱图